|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
|
31562808 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
|
31826955 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Functional Variant rs4442975 Modulating FOXA1 Binding Affinity Can Influence Bone Marrow Suppression during Neoadjuvant Chemotherapy for Luminal A Type Breast Cancer.
|
30881995 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further, we demonstrated that FOXA1 attenuation was involved in transcriptional downregulation of proapoptotic Bim and thus suppressed breast cancer cell apoptosis.
|
30793308 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
FOXA1 was reported to facilitate or reprogram ERα binding, thus playing a key function in breast cancer progression.
|
31029427 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, our results indicate that FOXA1 could be a useful biomarker to predict prognosis in breast cancer patients.
|
30941644 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer metastases (n = 164) from various anatomical sites were retrospectively analyzed by immunohistochemistry for FOXA1, Nestin and GATA3 expression.
|
30819139 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetic ablation of mammary ducts through foxa1 prevents breast cancer occurrence.
|
30906639 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.
|
31644911 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Through <i>in vitro</i> examination of the expression pattern at both transcriptional and translational levels, patient relapse-free survival analysis, immunohistochemistry staining and prediction power assessment using clinical samples, as well as functional studies, we systematically compared the role of FOXA1 in identifying triple negative and luminal type of breast cancers and explored the mechanisms driving such functionalities.
|
31182923 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Altered FOXA1 levels contribute to endocrine-resistant breast cancer, where it maintains ER-chromatin interactions, even in contexts in which cells are refractory to ER-targeted drugs.
|
30840881 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
This is in line with other studies suggesting these SNPs as risk-associated polymorphisms which may lead to a change in the affinity of FOXA1, as a distal enhancer, to <i>TOX3</i> and thus change in <i>TOX3</i> expression, which can eventually affect the risk of breast cancer.
|
31338012 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The analysis revealed already well-established associations with XBP1 and FOXA1, but also identified a strong association with CT62, a potential immunotherapeutic target with few previous associations with breast cancer.
|
30760519 |
2019 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Functional Variant rs4442975 Modulating FOXA1 Binding Affinity Can Influence Bone Marrow Suppression during Neoadjuvant Chemotherapy for Luminal A Type Breast Cancer.
|
30881995 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The analysis revealed already well-established associations with XBP1 and FOXA1, but also identified a strong association with CT62, a potential immunotherapeutic target with few previous associations with breast cancer.
|
30760519 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This is in line with other studies suggesting these SNPs as risk-associated polymorphisms which may lead to a change in the affinity of FOXA1, as a distal enhancer, to <i>TOX3</i> and thus change in <i>TOX3</i> expression, which can eventually affect the risk of breast cancer.
|
31338012 |
2019 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
|
31562808 |
2019 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
|
31826955 |
2019 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Altered FOXA1 levels contribute to endocrine-resistant breast cancer, where it maintains ER-chromatin interactions, even in contexts in which cells are refractory to ER-targeted drugs.
|
30840881 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.
|
31644911 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetic ablation of mammary ducts through foxa1 prevents breast cancer occurrence.
|
30906639 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, our results indicate that FOXA1 could be a useful biomarker to predict prognosis in breast cancer patients.
|
30941644 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FOXA1 was reported to facilitate or reprogram ERα binding, thus playing a key function in breast cancer progression.
|
31029427 |
2019 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer metastases (n = 164) from various anatomical sites were retrospectively analyzed by immunohistochemistry for FOXA1, Nestin and GATA3 expression.
|
30819139 |
2019 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further, we demonstrated that FOXA1 attenuation was involved in transcriptional downregulation of proapoptotic Bim and thus suppressed breast cancer cell apoptosis.
|
30793308 |
2019 |